Across TCGA pan-cancer cohorts, ZBED1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ZBED1 data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher ZBED1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZBED1 expression acts as an unfavorable survival marker, although some lineages such as SKCM and UCEC show a favorable association.

LIHC, SKCM, and UCEC are the cancer types where ZBED1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.140	0.557	.005	6	view →
SKCM	DFS	Median	All	0.457	0.193	.005	3	view →
UCEC	DFS	Median	All	0.784	0.633	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: ZBED1 tumor-vs-normal RNA expression · all ZBED1 data types